---
title: "Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Access and coverage questions"
description: "Access and coverage questions on Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Access and billing and Access and support. Questions: What are the NDC codes for KEYTRUDA? Is there a KEYTRUDA patient support program? Who can answer KEYTRUDA reimbursement and copay assistance questions? 3 questions quoted from 3 sources."
canonical: "https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/access-and-coverage"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Keytruda (pembrolizumab) in high-risk early-stage triple-negative breast cancer: Access and coverage questions

Manufacturer: Merck Sharp & Dohme LLC  
Prescribing information: [Keytruda](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf)

## Access and billing

<a id="keytruda-ndc"></a>

### What are the NDC codes for KEYTRUDA?

> “KEYTRUDA injection (clear to slightly opalescent, colorless to slightly yellow solution):
> Carton containing one 100 mg/4 mL (25 mg/mL), single-dose vial (NDC 0006-3026-02)
> Carton containing two 100 mg/4 mL (25 mg/mL), single-dose vials (NDC 0006-3026-04)”

Source: [KEYTRUDA: Prescribing information, page 195, captured 2026-11-13](https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf#page=195)

## Access and support

<a id="keytruda-patient-support"></a>

### Is there a KEYTRUDA patient support program?

> “Once treatment begins, a patient may feel unprepared. My Merck Support is designed to provide patients who are prescribed KEYTRUDA or KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) Injection 165 mg + 2,000 units/mL with educational resources, practical tips, and helpful tools during treatment.
> Once Enrolled, Your Patients Get Tailored Support, Including:
> A dedicated team member who can address nonmedical concerns and provide one-on-one phone support
> A starter kit that includes a treatment journal to help patients track and report their symptoms and a cookbook for meal planning and recipes
> Educational resources and practical tips that may help them feel prepared during treatment
> Connection to local services to help manage transportation, childcare, and more”

Source: [KEYTRUDA: My Merck Support for Patients on KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), captured 2026-11-13](https://www.keytrudahcp.com/resources/support-for-patients#:~:text=Once%20treatment%20begins%2C%20a%20patient,manage%20transportation%2C%20childcare%2C%20and%20more)

> “Patients who are prescribed KEYTRUDA or KEYTRUDA QLEX can learn more and enroll by calling 888-55-MyMRK (888-556-9675), Mon–Fri, 8am–8pm ET, or by visiting MyMerckSupport.com.”

Source: [KEYTRUDA: My Merck Support for Patients on KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), captured 2026-11-13](https://www.keytrudahcp.com/resources/support-for-patients#:~:text=Patients%20who%20are%20prescribed%20KEYTRUDA%20or%20KEYTRUDA%20QLEX%20can,ET%2C%20or%20by%20visiting%20MyMerckSupport.com.)

<a id="keytruda-reimbursement-copay-support"></a>

### Who can answer KEYTRUDA reimbursement and copay assistance questions?

> “Patient Access & Reimbursement Support
> The Merck Access Program may help answer questions about billing and coding for KEYTRUDA, and co-pay assistance for eligible patients.”

Source: [KEYTRUDA: KEYTRUDA® (pembrolizumab) | Official Website for Health Care Professionals, captured 2026-11-08](https://www.keytrudahcp.com/?group=bre#:~:text=Patient%20Access%20%26%20Reimbursement%20Support,co%2Dpay%20assistance%20for%20eligible%20patients.)

Note: The page links to the Merck Access Program site (merckaccessprogram-keytruda.com), a separate host outside the capture scope; program terms and eligibility are not quoted.

## Related pages
- [Medical information: Keytruda (pembrolizumab): High-risk early-stage triple-negative breast cancer](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer)
- [Indication](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/safety)
- [Specific populations](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/specific-populations)
- [Dosing and administration](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/keytruda--high-risk-early-stage-triple-negative-breast-cancer/guidelines)
